4.7 Article

Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012

期刊

EUROPEAN JOURNAL OF CANCER
卷 48, 期 18, 页码 3439-3447

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2012.07.002

关键词

Brain metastases; Clinical trail; Prophylaxis; EORTC

类别

资金

  1. Roche
  2. Novocure
  3. Merck Serono
  4. Comprehensive Cancer Center Vienna
  5. Genentech
  6. EU
  7. Dutch Epilepsy Foundation (NEF)
  8. Dutch Cancer Society (KWF Kankerbestrijding)
  9. Foundation NutsOhra
  10. Foundation STOPhersentumoren. nl
  11. National Brain Tumor Foundation/Tug McGraw Foundation
  12. UCB
  13. Sanofi-Aventis
  14. GSK

向作者/读者索取更多资源

Brain metastases (BM) occur in a significant proportion of cancer patients and are associated with considerable morbidity and poor prognosis. The trial design in BM patients is particularly challenging, as many disease and patient variables, statistical issues, and the selection of appropriate end-points have to be taken into account. During a meeting organised on behalf of the European Organisation for Research and Treatment of Cancer (EORTC), methodological aspects of trial design in BM were discussed. This paper summarises the issues and potential trial strategies discussed during this meeting and may provide some guidance for the design of trials in BM patients. (C) 2012 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据